The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
2-Phenyl-N-(5-{[(3R)-1-[5-(2-phenylacetamido)-1,3,4-thiadiazol-2-yl]pyrrolidin-3-yl]amino}-1,3,4-thiadiazol-2-yl)acetamide ID: ALA3770355
PubChem CID: 118988615
Max Phase: Preclinical
Molecular Formula: C24H24N8O2S2
Molecular Weight: 520.64
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: O=C(Cc1ccccc1)Nc1nnc(N[C@@H]2CCN(c3nnc(NC(=O)Cc4ccccc4)s3)C2)s1
Standard InChI: InChI=1S/C24H24N8O2S2/c33-19(13-16-7-3-1-4-8-16)26-22-29-28-21(35-22)25-18-11-12-32(15-18)24-31-30-23(36-24)27-20(34)14-17-9-5-2-6-10-17/h1-10,18H,11-15H2,(H,25,28)(H,26,29,33)(H,27,30,34)/t18-/m1/s1
Standard InChI Key: XKAUHJUBYCZSGD-GOSISDBHSA-N
Molfile:
RDKit 2D
36 40 0 0 0 0 0 0 0 0999 V2000
-5.3802 -6.1539 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-5.7991 -4.7128 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-6.2110 -7.0199 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-3.9229 -6.5127 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.0944 -8.4623 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
-3.5047 -7.9514 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-4.4264 -9.1348 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.5857 -10.3771 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.1617 -9.9480 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.9758 -10.8678 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.2469 -8.7527 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
0.7673 -8.8452 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.4117 -10.3025 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.6878 -11.0910 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.8320 -10.1210 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6747 -6.1134 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
3.1332 -7.5416 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6332 -7.5468 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.1017 -6.1218 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
3.8912 -5.2578 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5951 -3.0039 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5973 -1.5031 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.5548 -3.6021 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.8933 -3.7570 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
1.2990 -0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.2990 0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0000 1.5000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2990 0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.2990 -0.7500 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.0000 -1.5000 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-7.2564 -4.3540 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-7.6772 -2.9142 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-9.1344 -2.5586 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-10.1710 -3.6428 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-9.7503 -5.0826 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-8.2931 -5.4382 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
1 3 2 0
1 4 1 0
5 6 1 0
6 7 2 0
7 8 1 0
8 9 2 0
5 9 1 0
11 12 1 0
12 13 1 0
13 14 1 0
14 15 1 0
11 15 1 0
16 17 1 0
17 18 2 0
18 19 1 0
19 20 2 0
16 20 1 0
21 22 1 0
21 23 2 0
21 24 1 0
25 26 1 0
26 27 2 0
27 28 1 0
28 29 2 0
29 30 1 0
25 30 2 0
22 25 1 0
20 24 1 0
11 17 1 0
13 10 1 1
9 10 1 0
4 6 1 0
31 32 1 0
32 33 2 0
33 34 1 0
34 35 2 0
35 36 1 0
31 36 2 0
2 31 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 520.64Molecular Weight (Monoisotopic): 520.1464AlogP: 3.44#Rotatable Bonds: 9Polar Surface Area: 125.03Molecular Species: NEUTRALHBA: 10HBD: 3#RO5 Violations: 1HBA (Lipinski): 10HBD (Lipinski): 3#RO5 Violations (Lipinski): 1CX Acidic pKa: 6.78CX Basic pKa: 0.02CX LogP: 3.74CX LogD: 2.84Aromatic Rings: 4Heavy Atoms: 36QED Weighted: 0.31Np Likeness Score: -1.52
References 1. McDermott LA, Iyer P, Vernetti L, Rimer S, Sun J, Boby M, Yang T, Fioravanti M, O'Neill J, Wang L, Drakes D, Katt W, Huang Q, Cerione R.. (2016) Design and evaluation of novel glutaminase inhibitors., 24 (8): [PMID:26988803 ] [10.1016/j.bmc.2016.03.009 ] 2. Finlay MRV, Anderton M, Bailey A, Boyd S, Brookfield J, Cairnduff C, Charles M, Cheasty A, Critchlow SE, Culshaw J, Ekwuru T, Hollingsworth I, Jones N, Leroux F, Littleson M, McCarron H, McKelvie J, Mooney L, Nissink JWM, Perkins D, Powell S, Quesada MJ, Raubo P, Sabin V, Smith J, Smith PD, Stark A, Ting A, Wang P, Wilson Z, Winter-Holt JJ, Wood JM, Wrigley GL, Yu G, Zhang P.. (2019) Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models., 62 (14): [PMID:31199640 ] [10.1021/acs.jmedchem.9b00260 ]